Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers. (Q52870398)

9 May 2018

title

Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers. (English)

1 reference

9 May 2018

0 references

11

1 reference

9 May 2018

Dag Aarsland

14

1 reference

9 May 2018

Bengt Winblad

10

object named as

Bengt Winblad

1 reference

9 May 2018

9

Kina Höglund

1 reference

9 May 2018

author name string

Walid Tajeddinn

1

1 reference

9 May 2018

Seyed-Mohammad Fereshtehnejad

2

1 reference

9 May 2018

Mohammed Seed Ahmed

3

1 reference

9 May 2018

Takashi Yoshitake

4

1 reference

9 May 2018

Jan Kehr

5

1 reference

9 May 2018

Tasmin Shahnaz

6

1 reference

9 May 2018

Micha Milovanovic

7

1 reference

9 May 2018

Homira Behbahani

8

1 reference

9 May 2018

Vesna Jelic

12

1 reference

9 May 2018

Petter Järemo

13

1 reference

9 May 2018

publication date

4 May 2016

1 reference

9 May 2018

Journal of Alzheimer's Disease

published in

1 reference

9 May 2018

volume

53

1 reference

9 May 2018

issue

2

1 reference

9 May 2018

page(s)

621-630

1 reference

9 May 2018

https://api.crossref.org/works/10.3233%2FJAD-160022

1 reference

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Cerebrospinal fluid biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Alzheimer's disease is a synaptic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

5-HT1B and other related serotonergic proteins are altered in APPswe mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

The serotonergic system in ageing and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

The contribution of platelet studies to the understanding of disease mechanisms in complex and monogenetic neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Platelets and psychiatry: lessons learned from old and new studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Platelets provide human tissue to unravel pathogenic mechanisms of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Peripheral serotonin in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Platelet MAO-B activity and serotonin content in patients with dementia: effect of age, medication, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Alzheimer and platelets: low-density platelet populations reveal increased serotonin content in Alzheimer type dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Low-density platelet populations demonstrate low in vivo activity in sporadic Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

E- and P-selectin: differences, similarities and implications for the design of P-selectin antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Cornell Scale for Depression in Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Identification of low-density platelet populations with increased reactivity and elevated alpha-granule content.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Platelet density distribution in essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Derivatization chemistries for determination of serotonin, norepinephrine and dopamine in brain microdialysis samples by liquid chromatography with fluorescence detection

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Subjective memory complaints in Chinese subjects with mild cognitive impairment and early Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Decreased platelet serotonin concentration in Alzheimer's disease with involuntary emotional expression disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Serotonin uptake in the blood platelets of Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Serotonin uptake and its kinetics in platelets of women with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

Mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-160022

21 January 2018

Identifiers

DOI

10.3233/JAD-160022

1 reference

9 May 2018

PubMed ID

27163811

1 reference

9 May 2018